Technical Analysis for IMM - Immupharma Plc

Grade Last Price % Change Price Change
D 2.98 -1.33% -0.04
IMM closed down 1.33 percent on Friday, January 27, 2023, on approximately normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Up

Date Alert Name Type % Chg
Boomer Buy Setup Bullish Swing Setup 0.00%
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Overbought Stochastic Strength 0.00%
Jack-in-the-Box Bullish Bullish Swing Setup -1.33%
Stochastic Reached Overbought Strength -1.33%
Upper Bollinger Band Walk Strength -1.33%
Inside Day Range Contraction -1.33%

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
1.5x Volume Pace 1 day ago
Down 5% 2 days ago
Down 3% 2 days ago
Down 2% 2 days ago
Down 1% 2 days ago

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Immupharma Plc Description

ImmuPharma plc is a drug discovery and development company. The Company is focused on the development of drugs, primarily based on peptide therapeutics, to treat serious medical conditions such as autoimmune diseases. The Company has approximately five drug candidates in development, over two platform technologies and approximately 70 patents. Lupuzor is the Company's drug candidate and is a treatment for lupus, and life threatening auto immune disease. The Company's treatment for cancer, IPP-204106, has completed a Phase I/IIa study in cancer patients in France. Its compound IPP-102199 for pain relief is designed as a non-addictive replacement for morphine and other opioids, and is in pre-clinical development. Its treatment for inflammatory and allergic disorders (IPP-201007) is in early stage development. Its compound IPP-203101 is an antibiotic against methicillin-resistant staphylococcus aureus (MRSA) and other infections. The Company's research operations are in France.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Pain Medicine Cement Disease Clinic Cancer Earl Medical Specialties Drugs Diseases Mr Drug Discovery Autoimmune Diseases Infection Antibiotic Disorders Infectious Diseases Patent Infections Lupus Antibiotics Bacterial Diseases Healthcare Associated Infections Methicillin Opioids Staphylococcus Aureus

Is IMM a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 9.5
52 Week Low 1.36
Average Volume 2,234,690
200-Day Moving Average 4.51
50-Day Moving Average 2.25
20-Day Moving Average 2.42
10-Day Moving Average 2.68
Average True Range 0.36
RSI 62.12
ADX 30.26
+DI 28.59
-DI 11.31
Chandelier Exit (Long, 3 ATRs) 2.22
Chandelier Exit (Short, 3 ATRs) 2.73
Upper Bollinger Bands 3.14
Lower Bollinger Band 1.71
Percent B (%b) 0.89
BandWidth 58.95
MACD Line 0.20
MACD Signal Line 0.11
MACD Histogram 0.0883
Fundamentals Value
Market Cap 7.44 Million
Num Shares 250 Million
EPS -5.10
Price-to-Earnings (P/E) Ratio -0.58
Price-to-Sales 168.34
Price-to-Book 5.29
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 3.17
Resistance 3 (R3) 3.15 3.07 3.14
Resistance 2 (R2) 3.07 3.02 3.08 3.13
Resistance 1 (R1) 3.02 2.99 3.05 3.04 3.12
Pivot Point 2.94 2.94 2.95 2.95 2.94
Support 1 (S1) 2.89 2.89 2.92 2.91 2.83
Support 2 (S2) 2.81 2.86 2.82 2.82
Support 3 (S3) 2.76 2.81 2.81
Support 4 (S4) 2.78